- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07397728
TREX1-genmutaties en hun rol bij systemische lupus erythematosus
TREX1-genmutaties en hun rol in systemische lupus erythematosus: Een genotype-fenotype correlatiestudie
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Cutaneous lesions are among the earliest and most frequent features of SLE, with over 70% of patients developing mucocutaneous involvement during their disease course.
The presence and severity of cutaneous manifestations have been associated with specific autoantibodies, such as anti-Ro/SSA and anti-dsDNA, which may reflect underlying genetic susceptibility.
Recent studies have also implicated gene polymorphisms in IRF5, STAT4, TREX1, and TNFA in the pathogenesis of cutaneous SLE phenotypes.
Defective TREX1 exonuclease activity, leading to intracellular accumulation of DNA, may trigger type I interferon activation-a key mechanism in lupus pathophysiology.
Despite the extensive global literature, data from Egyptian patients remain limited, especially regarding the relationship between TREX1 gene variants and cutaneous lupus phenotypes.
Understanding how autoantibody profiles and gene polymorphisms relate to clinical features and disease activity could enhance early diagnosis, predict flares, and improve personalized therapy.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
South Valley
-
Qina, South Valley, Egypte
- Qina University hospital, South Valley University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
- Group A: 60 adults (18-60 years) diagnosed with SLE based on 2019 EULAR/ACR criteria, each with at least one cutaneous manifestation.
- Group B: 30 age- and sex-matched healthy controls with no personal or family history of autoimmune disease and negative ANA and anti-dsDNA.
Beschrijving
Inclusion Criteria:
- Adult aged 18-60 years
- Diagnosed as SLE per 2019 EULAR/ACR classification criteria.
- Presence of at least one cutaneous manifestation (acute, subacute, or chronic).
- Willing to provide written informed consent for participation and genetic testing
Exclusion Criteria:
- Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).
- Systemic infection, malignancy, or pregnancy.
- Use of biologic therapy or immunosuppressive pulses within one month.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_CONTROL
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Group A : (Systemic Lupus Erythrematosus)
About 90 patients diagnosed with SLE based on 2019 EULAR/ACR criteria, each with at least one cutaneous manifestation. |
To assess the prevalence of selected autoantibodies as (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) and TREX1 gene polymorphisms in SLE patients, and their association with clinical features and disease activity
Andere namen:
|
|
Group B (Healthy Controls)
90 age- and sex-matched healthy controls with no personal or family history of autoimmune disease and negative ANA and anti-dsDNA. |
To assess the prevalence of selected autoantibodies as (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) and TREX1 gene polymorphisms in SLE patients, and their association with clinical features and disease activity
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Systemic Lupus Erythematosus Assessment
Tijdsspanne: 3 Months
|
Assessment of disease activity in Systemic Lupus Erythematosus (SLE) using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). SLEDAI-2K as follows : 1-5 is Mild disease activity 6-10 is Moderate disease activity 11 or more is Severe disease activity |
3 Months
|
|
TREX1 gene polymorphism and SLE
Tijdsspanne: 3 Months
|
Assessment the association between TREX1 gene polymorphism and systemic lupus erythematosus susceptibility |
3 Months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Eisa Mohammed Hegazy, Professor, Dermatology, Venereology and Andrology. Faculty of Medicine,Qena University
- Studie directeur: Mohammed Hosny Hassan, Professor, Biochemistry ,Qena faculty of medicine ,south valley university
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TREX1 Gene
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .